Microglia and Macrophages in Glioblastoma: Landscapes and Treatment Directions

Microglia and Macrophages in Glioblastoma Academic Background Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system, characterized by high invasiveness and lethality. Despite standard treatments such as surgery, chemotherapy, and radiotherapy, the survival rate of patients remains extremely limited, with a medi...

Integrative Analysis of Ewing’s Sarcoma Reveals the MIF-CD74 Axis as a Target for Immunotherapy

Discovery of a New Immunotherapy Target for Ewing Sarcoma Background Introduction Ewing sarcoma (Ewing’s sarcoma, EWS) is a common pediatric bone cancer, accounting for approximately 2% of childhood cancers. Despite significant advances in immune checkpoint inhibitors (ICIs) and CAR-T cell therapy in various cancers, their efficacy in Ewing sarcoma...

Induction of Tertiary Lymphoid Structures in the Glioma Microenvironment and Their Role in Anti-Glioma Immunity

Induction of Tertiary Lymphoid Structures in Glioma Immunotherapy and Their Anti-Tumor Immune Effects Background Introduction Glioma is a highly malignant brain tumor characterized by limited lymphocyte infiltration in the tumor microenvironment (glioma microenvironment, GME), presenting an “immune desert” state. This characteristic makes glioma in...

Integration of Multi-Omics Data Reveals the Role of Efferocytosis in Lung Adenocarcinoma Prognosis and Immunotherapy

Research Report on Efferocytosis Features and Their Prognostic and Immunotherapy Associations in Lung Adenocarcinoma Background and Research Motivation Lung cancer is a leading cause of cancer-related mortality worldwide, with lung adenocarcinoma (LUAD) being the most common histological subtype. Due to the insidious nature of the disease and lack ...

Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy

Long-term Intravenous Anti-CD20 Antibody Therapy Assessment in a French Multiple Sclerosis Cohort Background and Research Motivation Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease affecting the central nervous system, leading to varying degrees of physical and cognitive impairment. Recent Phase II and III clinical trials of...

Targeting SNRNP200-Induced Splicing Dysregulation as an Immunotherapy Opportunity for Glycolytic Triple-Negative Breast Cancer

Targeting SNRNP200-Induced Splicing Dysregulation: A New Strategy for Immunotherapy in Glycolytic Triple-Negative Breast Cancer Background Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by extremely high recurrence and mortality rates. Despite significant recent advances in research on TNBC subty...

Epitope Editing Protects Hematopoietic Cells from CD123 Immunotherapy for Acute Myeloid Leukemia

Epitope Prime Editing Shields Hematopoietic Cells from CD123 Immunotherapy: A Novel Therapeutic Strategy for Acute Myeloid Leukemia Research Background and Problem Statement Acute Myeloid Leukemia (AML) is a malignant blood disease characterized by the abnormal differentiation of myeloid hematopoietic stem and progenitor cells (HSPCs). Its incidenc...

Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells

Background Introduction Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with a five-year survival rate of less than 20%, and treatment options are extremely limited. Traditional targeted drug therapies, such as Sorafenib and other kinase inhibitors, have been used to treat HCC, but their efficacy is limited and diffi...

Fibrotic Response to Anti-CSF-1R Therapy Potentiates Glioblastoma Recurrence

Fibrotic Response to Anti-CSF-1R Therapy Potentiates Glioblastoma Recurrence

Fibrotic Response Induced by Anti-CSF-1R Treatment Promotes Glioblastoma Recurrence Background Introduction Glioblastoma (GBM) is a highly aggressive and malignant primary tumor of the central nervous system. Although current standard treatments include surgical resection, Temozolomide chemotherapy, and fractionated radiotherapy, the median surviva...

Fusobacterium nucleatum Facilitates Anti-PD-1 Therapy in Microsatellite Stable Colorectal Cancer

Fusobacterium nucleatum Promotes Anti-PD-1 Therapy in Microsatellite-Stable Colorectal Cancer Background Introduction With the rise of immune checkpoint blockade (ICB) therapy, a new dawn has emerged in cancer treatment. However, despite the approval of PD-1 targeting drugs (e.g., Pembrolizumab) for certain types of colorectal cancer (CRC) patients...